Research has revealed that GK921, a TGM2-specific inhibitor, blocked mesenchymal transdifferentiation and showed significant therapeutic efficacy in a mouse model of glioma stem cells (Johnson et al., 2008). This evidence concerns the gene TGM2 and central nervous system cancer.